Altre lingue Shanghai Junshi Biosciences Co., Ltd. Deutsche Boerse AG

Azioni

8SJ

CNE100003FF7

Mercato chiuso - Deutsche Boerse AG Altri mercati azionari 09:59:02 14/06/2024			Variaz. 5gg	Var. 1 gen.
1,4 ^EUR	+1,45%		+2,19%	-46,15%

13/06	Il farmaco antitumorale di Junshi Biosciences ottiene il certificato di registrazione dall'autorità di regolamentazione cinese	MT
12/06	Shanghai Junshi Biosciences Co., Ltd. riceve il Certificato di registrazione del farmaco rilasciato dall'Amministrazione nazionale dei prodotti medici	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator	13/06
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration	12/06
Junshi Bio Achieves Primary Endpoints in Phase 3 Trial of Liver Cancer Treatment	12/06
Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results	12/06
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint	12/06
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma	11/06
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	25/04
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab	25/04
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region	24/04
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes	24/04
Junshi Biosciences Gets Nod to Register Toripalimab Injection	08/04
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA	03/04
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection	02/04
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.	02/04
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates	29/03
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates	29/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Shanghai Junshi Biosciences Co., Ltd. Deutsche Boerse AG

Azioni

8SJ

CNE100003FF7

Altre lingue

Filtri